Did you know ASTCT webinars are free to register for? We have a full calendar of upcoming webinars related to #HCT, #CART, #pharmacy, #Tandem25 sessions and more. View all webinars and register to attend one this month: www.astct.org/Meetings/Mee... #OncSky #HemeSky #MedSky

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance @pennmedicine.bsky.social @astct.bsky.social #Tandem25
#MultipleMyeloma #MMSM
www.onclive.com/view/ide-cel...

Check out incredible advances from MSK physicians and scientists that were presented at #Tandem25! Congrats to Sergio Giralt on giving the honorary Mortimer M. Bortin Lecture about the rapid advances that have changed transplant practice in the past three decades. @drmiguelperales.bsky.social

Great to see @mskcancercenter.bsky.social team shine at #tandem25 meeting & honored to work with such a talented group of colleagues

Orca-Q Delivers Early Evidence of GVHD Risk Mitigation in Hematologic Malignancies Amandeep Salhotra, MD, discusses data that have demonstrated the anti-GVHD activity of post-transplant Orca-Q in patients with hematologic malignancies.

Orca-Q Delivers Early Evidence of GVHD Risk Mitigation in Hematologic Malignancies @cityofhope.bsky.social #Tandem25 #oncology www.onclive.com/view/orca-q-...

🧬 #Tandem25 Recap: This session explored the promise of next-generation sequencing in TID, while also addressing key challenges.

Learn more: ow.ly/MBjM50V6jnE

Last week, Roswell Park experts gathered with top specialists at #TANDEM25 for Transplantation and Cellular Therapy, hosted by @astct.bsky.social and @cibmtr.bsky.social.

We’re so proud of our team for sharing their expertise and innovations on this big stage!

Today is the 3nd annual #GVHDday. This Day was established to symbolize an enduring solidarity with the GVHD community.

Help amplify the voices affected by GVHD & share this message.

🌐 Visit GVHDalliance.org to get involved.

#GVHDconnect4hope #GVHDAlliance #aGVHD #BMT #HSCT #HCT #bmtsm #Tandem25

What a wonderful #Tandem25! As always, the best of the conference is in the conversations and brainstorming between and outside the sessions; so wonderful to reconnect with mentors, friends, acquaintances from around the world in one of the most beautiful places I have ever visited.

Great way to end #tandem25 in Hawaii by hiking Koko Crater with Boston colleagues.

Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.

Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance @algarfall.bsky.social @pennmedicine.bsky.social @penncancer.bsky.social @astct.bsky.social #TANDEM25 #hematology
www.onclive.com/view/ide-cel...

Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant #TANDEM25 www.onclive.com/view/non-mye...

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies @astct.bsky.social @stanfordmedicine.bsky.social #TANDEM25 #oncology www.onclive.com/view/foxp3-h...

Another great Tandem meeting in the books. Congratulations to the organizing committee chaired by Melody Smith & Marie Bleakley - see everyone in Salt Lake City next year #tandem25

Also relevant in non-malignant conditions-- at Q&A session re: Lenmeldy for MLD, average time to approval is 6-12 months, which means 6-12 months of neurodegeneration before cure.

"This is not going to be as effective as it's supposed to be if we don't have early diagnosis and procedures" #Tandem25

#tandem25 #bmtsm: Amazingly, the @cibmtr.bsky.social Immunobiology working committee meeting, which used to be a 4-hour marathon, was finished today in just over an hour. Have we answered all the questions, or is just another sign that HLA is no longer king in the PTCy era?

Fascinating talk on how to predict & optimize cell/gene therapy capacity/throughput from Julie Porter @danafarber.bsky.social.

In addition to all the plenary session payers worried by #celltx #genetx costs-- how do hospitals balance urgency & risk that if they treat they won't get paid? #tandem25

#tandem25 #bmtsm Mehta: in haploHCT for leukemia/MDS variables that favorably impact outcome included B-leader matching, DRB1-mismatching, DQB1-matching, and DPB1 non-permissive mismatching. When you have these data available, there is an online calculator to help with donor selection.

#tandem25 #bmtsm Perales: ECP 12mo FFS 61% in recent meta analysis. Responses can take many months.

#tandem25 #bmtsm Perales: Nice summary table for the four agents approved for treatment of SR-cGVHD.

#tandem25 #bmtsm Perales: Axatilimab ORR 74% at approved dose, and like Bel showing responses in sclerodermatous cGVHD. Although there were delays between approval and market available it is now in the pipeline.

#tandem25 #bmtsm Perales: Belumosudil ORR 73-77% with responses in all organs and subgroups involved. Particularly favorable for sclerotic cGVHD.

#tandem25 #bmtsm Perales: In REACH 3 Ph3 RCT Rux ORR at 24wks 50% with very significant improvement in failure free OS.

#tandem25 #bmtsm Perales: so far only Rux has been studied in Ph3 RCT for treatment of SR-cGVHD. Both Ibrutinib and Belumosudil approved on Ph2 studies without comparator. Real world data with IBR not as favorable as on study.

#tandem25 #bmtsm Perales: cGVHD incidence decreasing significantly due to advent of PTCY, TCD (in vivo and ex vivo), etc. Risk factors for cGVHD now better understood. NIH defined and atypical (some not so atypical, IMO, particularly muscle cramps) features of cGVHD shown nicely in 3rd slide.

#tandem25 #bmtsm Perales: recent TCT journal issue dedicated for subspecialty mgmt of cGVHD. Good ref for ophthalmology, pulm, derm, etc.

#tandem25 #bmtsm Gandhi: Apraglutide (GLP2i) showed 58% ORR (55% for gut GVHD) at d28 in STARGAZE trial.

#tandem25 #bmtsm Gandhi: Remestemcel MSC in SR-aGVHD show 70% ORR at d28. Approved now for Peds (but not adult pts, so a CTN study is coming to address this).

#tandem25 #bmtsm Gandhi: Ruxolitinib is preferred therapy for SR-aGVHD based on REACH1+2 studies. Rux Day 28 ORR 62%, 40% at d56 in REACH 2.